Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Cancer Cell · 2024-05 · 42 (5) · 904-914.e9
DOI: 10.1016/j.ccell.2024.03.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-05. Verfasst von Avishay Spitzer und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel; Department of Oncology, Tel Aviv Sourasky Medical Center…. Hauptthemen laut MEDLINE: Oligodendroglioma, Isocitrate Dehydrogenase, Cell Differentiation, Mutation. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Sanofi, European Commission.
Abstract (Originalsprache)
A subset of patients with IDH-mutant glioma respond to inhibitors of mutant IDH (IDHi), yet the molecular underpinnings of such responses are not understood. Here, we profiled by single-cell or single-nucleus RNA-sequencing three IDH-mutant oligodendrogliomas from patients who derived clinical benefit from IDHi. Importantly, the tissues were sampled on-drug, four weeks from treatment initiation. We further integrate our findings with analysis of single-cell and bulk transcriptomes from independent cohorts and experimental models. We find that IDHi treatment induces a robust differentiation toward the astrocytic lineage, accompanied by a depletion of stem-like cells and a reduction of cell proliferation. Furthermore, mutations in NOTCH1 are associated with decreased astrocytic differentiation and may limit the response to IDHi. Our study highlights the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas and suggests a genetic modifier that may improve patient stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel; Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv…
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neuro…
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.
- New York Genome Center, New York, NY, USA; Weill Cornell Medicine, New York, NY, USA.
- Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for Neuro-On…
Förderung
- NCI NIH HHS
- Sanofi
- European Commission
- Human Frontier Science Program
- National Cancer Institute
- NIH
- Massachusetts General Hospital
- Council for Higher Education
Zitieren
APA
Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., Lee, J. J. Y., Mylvaganam, R., Lee Servis, R., Fung, J. M., Lee, C. K., Nagashima, H., Miller, J. J., Arrillaga-Romany, I., Louis, D. N., …, & Tirosh, I. (2024). Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell, 42(5), 904-914.e9. https://doi.org/10.1016/j.ccell.2024.03.008
Vancouver
Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R, et al. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell. 2024;42(5):904-914.e9. doi:10.1016/j.ccell.2024.03.008
BibTeX
@article{Spitzer2024,
author = {Spitzer, Avishay and Gritsch, Simon and Nomura, Masashi and Jucht, Alexander and Fortin, Jerome and Raviram, Ramya and Weisman, Hannah R and Gonzalez Castro, L Nicolas and Druck, Nicholas and Chanoch-Myers, Rony and Lee, John J Y and Mylvaganam, Ravindra and Lee Servis, Rachel and Fung, Jeremy Man and Lee, Christine K and Nagashima, Hiroaki and Miller, Julie J and Arrillaga-Romany, Isabel and Louis, David N and Wakimoto, Hiroaki and Pisano, Will and Wen, Patrick Y and Mak, Tak W and Sanson, Marc and Touat, Mehdi and Landau, Dan A and Ligon, Keith L and Cahill, Daniel P and Suvà, Mario L and Tirosh, Itay},
title = {Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {5},
pages = {904--914.e9},
doi = {10.1016/j.ccell.2024.03.008}
}
EUVIMED